New U.S. Patent Allowance Granted to Aushon BioSystems for Microarray Printing of Complex Biological and Chemical Fluids
New Addition to Patent Portfolio Strengthens Aushon’s Leadership Position in Microarray Technology
Billerica, MA, (January 24, 2017) Aushon BioSystems – a leading provider of high sensitivity assays, instrumentation and services for multiplex quantitative detection of protein biomarkers, today announced US Patent No. 9,527,085 entitled “Apparatus and Method for Dispensing Fluid, Semi-Solid and Solid Samples” was issued by the U.S. Patent and Trademark Office (USPTO). This new patent, together with previously issued patents, solidifies Aushon’s leadership position in microarray printing of complex biological and chemical fluids.
The new invention enables Aushon to fabricate microarrays in a wide variety of formats and densities, including its proprietary circular array format utilized in its Ciraplex™ kits.
“This patent covers significant advancements in the use of solid pin printing in order to eliminate variability in spot size and intensity,” said Peter Honkanen, Founder and COO of Aushon. “These advancements are critical to achieving reproducible precision in clinical applications considering the fluid volumes carried by such solid deposition pins are in the picoliter to nanoliter range.”
Aushon’s technology is commercially available as an innovative 2470 Microarrayer. Fundamental to the internal manufacturing expertise, Aushon multiplex immunoassays demonstrate highly precise results even at femtogram/ml levels of detection.
“As a pioneer in multiplex immunoassays with superior femtogram/ml levels of detection, we see this new patent as further evidence of our core technology playing an important role in biomarker discovery and clinical applications,” said Susan Vogt, CEO. “We continue to invest in our research and development operations in order to meet the growing demands of our clinical and diagnostic customers and partners.”
About Aushon BioSystems
Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive biomarker content and ease-of-use, the Cira™ immunoassay platform is serving leading pharmaceutical companies, contract research organizations and clinical reference laboratories worldwide. Aushon products are used for applications in preclinical and clinical biomarker research accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in diagnostics. For more information go to: http://www.aushon.com
For more information, contact:
Regina M Reynolds,